Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05947474 · ClinicalTrials.gov registry record · Phase 1
ORB-011 In Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Cancer, sponsored by Orionis Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT05947474 is a Phase 1 study of Advanced Solid Cancer that is active but no longer recruiting, run by Orionis Biosciences. The registered enrollment target is 55 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05947474, a Phase 1 study of Advanced Solid Cancer, is active but no longer recruiting, sponsored by Orionis Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Conditions Studied
Interventions
- DRUG ORB-011
Study Locations (2)
Arizona
- Honor Health Research Institute - Scottsdale
Texas
- MD Anderson Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05947474
The ClinicalTrials.gov registry entry for NCT05947474 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orionis Biosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Cancer appearing as the primary indexed condition, and to 1 intervention - of which ORB-011 is the first listed.
NCT05947474 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT05947474 about?
NCT05947474 is a clinical study titled "ORB-011 In Patients With Advanced Solid Tumors". The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by ...
What is the current status of trial NCT05947474?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2023-08-21. Estimated completion is 2026-03.
What conditions does trial NCT05947474 study?
This clinical trial studies the following conditions: Advanced Solid Cancer.
What interventions are being tested in trial NCT05947474?
The interventions under investigation include: ORB-011 (DRUG).
Who is sponsoring clinical trial NCT05947474?
This trial is sponsored by Orionis Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05947474 being conducted?
This trial has 2 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.